Owens & Minor ‘in line with expectations’
By HME News Staff
Updated 7:35 AM CDT, Fri August 2, 2024
RICHMOND, Va. – Owens & Minor reported consolidated revenue of $2.7 billion for the second quarter of 2024, an increase of 4% year over year.
Of that, Patient Direct revenue was $660 million, an increase of 4%, driven by continued strong growth in diabetes and sleep supplies.
“Our Patient Direct segment performed in line with our expectations, and we expect the segment to benefit from seasonality and recent organic investments during the back half of the year,” said Edward A. Pesicka, president & CEO.
Other highlights from the quarter:
-
Adjusted EBITDA for the quarter was $127, representing year-over-year growth of 12%
-
The company has recently reaffirmed financial guidance for the full year:
-
Revenue for 2024 to be in a range of $10.5 billion to $10.9 billion
-
Adjusted EBITDA for 2024 to be in a range of $550 million to $590 million
-
Adjusted EPS for 2024 to be in a range of $1.40 to $1.70.
- Owens & Minor in July acquired Rotech Healthcare for $1.36 billion.
Comments